<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">27723559</PMID>
        <DateCompleted>
            <Year>2018</Year>
            <Month>02</Month>
            <Day>08</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>02</Month>
            <Day>08</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1872-9800</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>118</Volume>
                    <PubDate>
                        <Year>2016</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine</Title>
                <ISOAbbreviation>Appl Radiat Isot</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Deuteron induced Tb-155 production, a theranostic isotope for SPECT imaging and auger therapy.</ArticleTitle>
            <Pagination>
                <MedlinePgn>281-289</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S0969-8043(16)30790-4</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.apradiso.2016.09.030</ELocationID>
            <Abstract>
                <AbstractText>Several terbium isotopes are suited for diagnosis or therapy in nuclear medicine. Tb-155 is of interest for SPECT imaging and/or Auger therapy. High radionuclide purity is mandatory for many applications in medicine. The quantification of the activity of the produced contaminants is therefore as important as that of the radionuclide of interest. The experiments performed at the ARRONAX cyclotron (Nantes, France), using the deuteron beam delivered up to 34MeV, provide an additional measurement of the excitation function of the Gd-nat(d,x)Tb-155 reaction and of the produced terbium and gadolinium contaminants. In this study, we investigate the achievable yield for each radionuclide produced in natural gadolinium as a function of the deuteron energy. Other reactions are discussed in order to define the production route that could provide Tb-155 with a high yield and a high radionuclide purity. This article aims to improve data for the Gd-nat(d,x) reaction and to optimize the irradiation conditions required to produce Tb-155.</AbstractText>
                <CopyrightInformation>Copyright © 2016 Elsevier Ltd. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Duchemin</LastName>
                    <ForeName>C</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>SUBATECH, Ecole des Mines de Nantes, Université de Nantes, CNRS/IN2P3, Nantes, France. Electronic address: Charlotte.Duchemin@subatech.in2p3.fr.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Guertin</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>SUBATECH, Ecole des Mines de Nantes, Université de Nantes, CNRS/IN2P3, Nantes, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Haddad</LastName>
                    <ForeName>F</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>SUBATECH, Ecole des Mines de Nantes, Université de Nantes, CNRS/IN2P3, Nantes, France; GIP Arronax, 1 rue Aronnax, 44817 Saint-Herblain, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Michel</LastName>
                    <ForeName>N</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>SUBATECH, Ecole des Mines de Nantes, Université de Nantes, CNRS/IN2P3, Nantes, France; GIP Arronax, 1 rue Aronnax, 44817 Saint-Herblain, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Métivier</LastName>
                    <ForeName>V</ForeName>
                    <Initials>V</Initials>
                    <AffiliationInfo>
                        <Affiliation>SUBATECH, Ecole des Mines de Nantes, Université de Nantes, CNRS/IN2P3, Nantes, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2016</Year>
                <Month>09</Month>
                <Day>30</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Appl Radiat Isot</MedlineTA>
            <NlmUniqueID>9306253</NlmUniqueID>
            <ISSNLinking>0969-8043</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>06SSF7P179</RegistryNumber>
                <NameOfSubstance UI="D013725">Terbium</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>AR09D82C7G</RegistryNumber>
                <NameOfSubstance UI="D003903">Deuterium</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D003903" MajorTopicYN="N">Deuterium</DescriptorName>
                <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011829" MajorTopicYN="N">Radiation Dosage</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011876" MajorTopicYN="N">Radionuclide Generators</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019275" MajorTopicYN="N">Radiopharmaceuticals</DescriptorName>
                <QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011878" MajorTopicYN="N">Radiotherapy</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013725" MajorTopicYN="N">Terbium</DescriptorName>
                <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000068936" MajorTopicYN="N">Theranostic Nanomedicine</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Deuteron beam</Keyword>
            <Keyword MajorTopicYN="N">Gadolinium target</Keyword>
            <Keyword MajorTopicYN="N">Stacked-foil technique</Keyword>
            <Keyword MajorTopicYN="N">TALYS 1.6</Keyword>
            <Keyword MajorTopicYN="N">Terbium-155</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2016</Year>
                <Month>04</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2016</Year>
                <Month>09</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2016</Year>
                <Month>09</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2016</Year>
                <Month>10</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>2</Month>
                <Day>9</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2016</Year>
                <Month>10</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">27723559</ArticleId>
            <ArticleId IdType="pii">S0969-8043(16)30790-4</ArticleId>
            <ArticleId IdType="doi">10.1016/j.apradiso.2016.09.030</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>